Get the app
US › Healthcare

Longeveron LLC (LGVN)

US · Healthcare · Biotechnology

$1.39-7.33%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$287,000
Revenue YoY
-9.2%
Net profit
$-6.1M
EPS
$-0.19
EPS estimate
$-0.19
Net margin
-2,116.0%

EPS came in at -0.19 against a street estimate of -0.19 — a beat of 0.0%.

Key statistics

Market cap
$4.8M
Forward P/E
0.0
P/B
0.80
Book value
$3.28
EPS (TTM)
$-6.69
52-week high
$12.30
52-week low
$1.36
50-day MA
$5.35
200-day MA
$6.88
Beta
-0.20

Analyst view

Analysts rate Longeveron LLC a buy (1 buy, 1 hold, 0 sell out of 2) with an average price target of $61.25.

Shareholding

Insiders
14.80%
Institutions
22.50%

Largest institutional holders

FundStake
Millennium Management LLC4.25%
Logos Global Management LP4.04%
Vanguard Capital Management, LLC1.82%
BlackRock Inc0.70%
Geode Capital Management, LLC0.64%
Jane Street Group LLC0.60%
Vanguard Fiduciary Trust Co0.44%
Mariner Wealth Advisors LLC0.40%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Longeveron LLC — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-19.